Home Antibody All anti-BRCA1 antibodies
Anti-BRCA1 GAT Antibody Polyclonal
UltraMAB Antibodies - Validated with 10K Protein Chip
Also for BRCA1 (NM_007294)
|DNA immunization. This antibody is specific for the C Terminus Region of the target protein.|
||WB: 1:5000-1:20000; ELISA: 1:100-1:2000
|20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0|
|The fragment used for DNA immunization was expressed in E.coli and the purified protein fragment was used for affinity purification of the antibody. (Protein A or G Sepharose)
|This antibody was generated by SDIX's Genomic Antibody Technology ® (GAT). Learn about GAT
|Homo sapiens breast cancer 1, early onset (BRCA1), transcript variant 1|
|BRCAI; BRCC1; BROVCA1; IRIS; PNCA4; PPP1R53; PSCP; RNF53|
|BRCA1 (breast and ovarian cancer susceptibility protein 1) is a RING finger protein containing a BRCT domain. BRCA1 exists as a heterodimer with 22 possible isoforms. The full length protein has a reported molecular weight of 208 kD. BRCA1 localizes to the mitotic spindle microtubules, centriole walls, pericentriolar fibers at centrosomes. Unphosphorylated BRCA1 localizes on chromosomes from metaphase through telophase; phosphorylated BRCA1 resides in inner chromosomal structure, centrosome, cleavage furrow during prophase through telophase, and relocalizes to the perinuclear region when cells are subjected to IR or UV radiation in S phase. BRCA1 acts as a tumor suppressor and can function as a secreted growth inhibitory protein, participate in transcription coupled repair of oxidative DNA damage, X-chromosome inactivation, and can function as a E3 ubiquitin ligase. BRCA1 can be transcriptionally downregulated by Ets-2, Brg-1, and Hmga-1. BRCA1 can be modified by glycosylation, ubiquitination and phosphorylation by CDK4, ATM/ATR, cdk2, and hChk2. The BRCA1 protein has been reported to interact with RNA polymerase II holoenzyme and BARD1. BRCA1 contains at least two nuclear localization signals and is proposed to be a tumor suppressor protein. It is a serine phosphoprotein that undergoes hyperphosphorylation during late G1 and S phases of the cell cycle and is transiently dephosphorylated early after M phase. BRCA1 protein alters in a qualitative and quantitative manner during cell cycle progression. The amount of BRCA1 protein is highest during S phase and remains elevated toward G2 / M, before it declines in early G1 phase. Inherited loss of BRCA1 function confers an increased susceptibility for both breast and ovarian cancer.|
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western Blot: BRCA1 Antibody - Western Blot was performed using affinity purified SEQer BRCA1 antibody, aa(1439-1538) antibody. The lanes contain 5-30ug of a whole cell extract. Final concentration of antibodies = 0.1ug/ml (1:10,000 dilution). The blot was probed overnight with the SEQer BRCA1 antibody, aa(1439-1538) antibody. Blot was then washed according to protocol and probed with goat-anti-Rabbit-HRP conjugate at 1:5000 dilution, washed and developed using chemiluminescence (film exposure 5-30sec). The protein was detected as represented by the band shown.